Dimethyl Sulfoxide
Apexbio Technology LLC Eptifibatide 188627-80-7 10mM (in 1mL DMSO)
Eptifibatide is a cyclic heptapeptide belonging to the glycoprotein IIb/IIIa inhibitor category functioning as an antagonist of platelet adhesion by reversibly binding to the platelet glycoprotein IIb/IIIa receptor This receptor located on platelet surfaces mediates platelet aggregation through binding fibrinogen and von Willebrand factor processes essential in thrombus formation By blocking the GP IIb/IIIa receptor binding site Eptifibatide inhibits fibrinogen-dependent platelet cross-linking reducing platelet aggregation In biomedical research Eptifibatide serves as a pharmacological tool to investigate platelet function thrombosis mechanisms and related cardiovascular diseases in preclinical and clinical models
Apexbio Technology LLC Salubrinal 405060-95-9 10mM (in 1mL DMSO)
Salubrinal is a cell-permeable inhibitor of eukaryotic translation initiation factor 2 alpha (eIF2 ) dephosphorylation exhibiting an IC50 of approximately 15 M It prevents phosphatase complexes from removing phosphate groups from eIF2 thus maintaining its phosphorylated state and modulating protein synthesis during cellular stress responses Salubrinal is utilized experimentally in vitro to investigate apoptotic mechanisms related to endoplasmic reticulum (ER) stress For instance it provides cytoprotection against ER stress-induced apoptosis triggered by protein glycosylation inhibitors or ER-Golgi trafficking inhibitors In vivo murine models employ salubrinal to explore cellular processes underlying oxidative stress and nephrotoxicity induced by chemotherapeutic treatments through modulation of ER stress-associated apoptosis signaling pathways Currently no clinical trials involving salubrinal have been reported
Apexbio Technology LLC CPI-169 1450655-76-1 10mM (in 1mL DMSO)
CPI-169 is a selective small-molecule inhibitor targeting enhancer of zeste homolog 2 (EZH2) a catalytic component of polycomb repressive complex 2 (PRC2) By inhibiting EZH2 enzymatic activity CPI-169 suppresses methylation at histone H3 lysine 27 (H3K27me3) thereby altering chromatin structure and gene expression profiles Pharmacological experiments demonstrate inhibition of EZH2 with subnanomolar IC50 values and cellular studies indicate reductions of H3K27 trimethylation at nanomolar concentrations CPI-169 has been utilized experimentally to investigate EZH2-dependent epigenetic processes cell proliferation apoptosis pathways and therapeutic potential particularly in lymphoma and cancer biology studies employing in vitro and in vivo models
Apexbio Technology LLC UNC0638 1255580-76-7 10mM (in 1mL DMSO)
UNC0638 is a selective inhibitor of histone methyltransferases G9a and GLP enzymes responsible for mono- and dimethylation of histone H3 lysine-9 (H3K9) It inhibits G9a and GLP activity with IC50 values of 15 nM and 19 nM respectively UNC0638 reduces cellular H3K9 dimethylation levels demonstrated in MDA-MB-231 cells with an IC50 of 81 9 nM at 48 hours It has been utilized in models to study epigenetic regulation including neuroendocrine tumor xenografts and hair cell damage induced by aminoglycosides addressing roles of H3K9 methylation in disease pathogenesis and therapeutic responses
Apexbio Technology LLC Aprepitant 170729-80-3 10mM (in 1mL DMSO)
Aprepitant (MK-0869) is a highly selective antagonist of the neurokinin-1 (NK-1) receptor functioning by competitively inhibiting substance P (SP) an undecapeptide belonging to the tachykinin family from activating NK-1 receptors Its binding affinity for human NK-1 receptors is indicated by a dissociation constant (Kd) of approximately 86 pM In cellular models overexpressing NK-1 receptors including glioma (GAMG) neuroblastoma (SKN-BE2 IC50 19 6 M IMR-32 IC50 27 7 M KELLY IC50 30 4 M) retinoblastoma (Y-79 IC50 23 M WERI-Rb-1 IC50 31 2 M) pancreatic cancer (PA-TU-8902 IC50 27 4 M CAPAN-1 IC50 22 7 M) and colon cancer (SW-403 IC50 30 5 M) aprepitant application has been reported to inhibit tumor cell proliferation in vitro
Apexbio Technology LLC SP2509 1423715-09-6 10mM (in 1mL DMSO)
SP2509 (CAS 1423715-09-6) is a small molecule antagonist of lysine-specific demethylase 1 (LSD1/KDM1A) a histone-modifying enzyme responsible for demethylating mono- and dimethylated histone H3 lysine 4 (H3K4) SP2509 potently inhibits LSD1 activity (IC50 13 nM) without affecting monoamine oxidase isoforms MAO-A or MAO-B In acute myeloid leukemia (AML) cells SP2509 suppresses LSD1 function reduces colony formation induces apoptosis enhances promoter-specific H3K4 trimethylation and stimulates differentiation through upregulation of p53 p21 and C/EBP Its efficacy has been demonstrated in AML xenograft models supporting its utility as a tool compound for cancer research
Medchemexpress LLC Jq1 1Mm Dmso Reconstitution | HY-13030-10MM DMSO RECONS
Jq1 1Mm Dmso Reconstitution
Medchemexpress LLC Azd0780 10Mm 1Ml Dmso Reconst | HY-148673-10MM DMSO RECON
Azd0780 10Mm 1Ml Dmso Reconst
Medchemexpress LLC Jsh-23 10Mm 1Ml Dmso Solution | HY-13982-10MM 1ML DMSO
Jsh-23 10Mm 1Ml Dmso Solution
Apexbio Technology LLC ASC-J9(Synonyms: Dimethylcurcumin, GO-Y025, AR degrader enhancer ASC-J9), 10mM (in 1mL DMSO), CAS: 52328-98-0.
ASC-J9 (CAS 52328-98-0) is a small-molecule degrader targeting androgen receptor (AR) By promoting degradation of full-length AR and splice variants such as AR3/fAR ASC-J9 inhibits androgen receptor signaling pathways involved in castration-resistant prostate cancer (CRPC) progression and metastatic behavior ASC-J9 interferes with AR-dependent transcriptional modulation and AR-independent signaling pathways notably inhibiting STAT3 phosphorylation and CCL2 chemokine secretion thus reducing macrophage infiltration and prostate cancer invasiveness Research indicates ASC-J9 may represent an alternative therapeutic strategy for CRPC treatment and metastasis prevention
Apexbio Technology LLC Rucaparib (free base) 283173-50-2 10mM (in 1mL DMSO)
Rucaparib (free base) (CAS 283173-50-2) also known as AG014699 or PF-01367338 is a pharmacological inhibitor targeting poly(ADP-ribose) polymerase (PARP) a nuclear enzyme centrally involved in DNA damage signaling and base excision repair pathways By impeding PARP activity Rucaparib compromises DNA repair capacity leading to persistent DNA strand breaks as evidenced by increased gamma-H2AX and p53BP1 foci It has demonstrated radiosensitizing properties in prostate cancer cells notably those harboring PTEN deficiency or expressing ETS gene fusion proteins due partly to inhibition of non-homologous end-joining (NHEJ) DNA repair Rucaparib serves as a tool compound in oncology research to study chemosensitization and radiosensitization strategies
Apexbio Technology LLC MLN2238(Synonyms: Ixazomib, MLN-2238, Ninlaro, MLN9708, Ixazomib citrate), 10mM (in 1mL DMSO), CAS: 1072833-77-2.
MLN2238 (CAS number 1072833-77-2) is a dipeptidyl boronic acid derivative designed as a reversible inhibitor of the 5 subunit (chymotrypsin-like activity) of the 20S proteasome with reported IC50 and Ki values of 3 4 nM and 0 93 nM respectively At higher concentrations MLN2238 also targets the proteasome s 1 (caspase-like) and 2 (trypsin-like) subunits In preclinical studies using xenograft and genetically-engineered models of hematologic malignancies MLN2238 exhibited potent antitumor activity promoting apoptosis and suppressing pathways such as NF- B MLN2238 has research applications in oncology particularly against multiple myeloma and lymphoma including in bortezomib-resistant cell lines
Cell Signaling Technology DMSO (Dimethyl Sulfoxide), Sterile 10 ml
DMSO (Dimethyl Sulfoxide), Sterile 10 ml
